Hec Pharm H-Share Full Circulation Approved, Hong Kong Market Cap Expands Significantly

Hec Pharm Receives H-Share Full Circulation Filing, Market Cap Nearly Triples

On April 29, Hec Pharm announced that the company has received the H-share "full circulation" filing notice from the China Securities Regulatory Commission (CSRC). A total of approximately 208 million domestic shares have been approved for conversion into H-shares for listing and trading on the Hong Kong Stock Exchange, representing 36.05% of the company's total share capital. This key development marks an important step forward for the company on the capital markets front.

Tradable Shares Expand Substantially, Market Cap Rises Significantly

Upon completion of the full circulation, Hec Pharm's tradable shares will expand substantially. Based on the closing price on the announcement date, the company's Hong Kong market capitalization is projected to increase from approximately HK$4.705 billion to approximately HK$13.399 billion, a gain of nearly 185%.

Notably, this market cap scale has reached the inclusion thresholds for Stock Connect and the Hang Seng Index. If the company is subsequently included in relevant indices and the mutual market access mechanism, it would attract greater attention and capital inflows from both mainland and international institutional investors, further improving the stock's liquidity and valuation levels.

Strategic Significance of H-Share Full Circulation

H-share "full circulation" refers to the mechanism whereby mainland enterprises listed in Hong Kong convert their unlisted domestic shares into H-shares for trading on the HKEX. For Hec Pharm, this approval carries multiple strategic implications:

First, enhanced liquidity. The significant increase in the proportion of tradable shares following full circulation will help invigorate market trading and reduce the impact of block trades on the share price.

Second, optimized shareholder structure. With domestic shares converted to H-shares, existing shareholders can trade through the Hong Kong stock market. A more market-oriented and internationalized shareholder structure is conducive to improving corporate governance standards.

Third, unlocked capital channels. With market capitalization reaching the Stock Connect threshold, the company is poised for potential inclusion in the Shanghai-Shenzhen-Hong Kong Stock Connect program, thereby attracting southbound capital allocation and broadening its financing channels and investor base.

Industry Context and Market Outlook

In recent years, H-share full circulation reform has continued to advance, with an increasing number of mainland enterprises listed in Hong Kong completing this critical capital market transformation. For the pharmaceutical sector, full circulation not only expands individual companies' capital operation capabilities but also provides an opportunity for valuation reassessment across the entire industry in the Hong Kong stock market.

Market analysts note that following Hec Pharm's full circulation approval, attention should be paid in the short term to the disposition intentions and pace of former domestic shareholders, while the medium- to long-term focus should be on the company's fundamentals and whether it can be successfully included in Stock Connect and other key indices. If inclusion is achieved, it could bring sustained incremental capital flows and provide positive support for the company's valuation.